Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenC-CRM197 conjugate vaccine
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenC-CRM197 conjugate vaccine is a monovalent vaccine designed for the prevention of invasive disease caused by *Neisseria meningitidis* serogroup C. It consists of polysaccharide from the C serogroup of *Neisseria meningitidis* chemically conjugated to CRM197, which is a genetically detoxified variant of diphtheria toxin. The conjugation to CRM197 enhances immunogenicity by eliciting a T cell-dependent immune response, including immune memory, particularly in infants and young children, populations that respond poorly to plain polysaccharide vaccines. The primary indication is prevention of meningococcal group C disease.
- Brand names
- MeningitecMenjugate
- Other names
- Meningococcal C-CRM197 conjugate vaccineMenC-CRMMenC-CRM197MenC-CRM-197MenC-CRM 197
02
Targets
Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on MenC-CRM197 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenC-CRM197 conjugate vaccine.